• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients.
Conclusion: Elderly patients with NVAF in the U.S. who continued with apixaban treatment had a lower risk of MB-related hospitalization and lower MB- and stroke/SE-related medical costs compared to patients who switched to another OAC. PMID: 31120309 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - May 25, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants.
CONCLUSIONS: The incremental healthcare costs incurred by patients with versus without stroke/SE was nearly twice as high as those of patients with versus without MB. Moreover, each additional year up to 4 years after the first event was associated with an incremental cost for patients with a stroke/SE or MB event compared to those without an event. PMID: 30939954 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - April 5, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
ConclusionsMorbidly obese AF patients treated with rivaroxaban had comparable risk of ischemic stroke/systemic embolism and major bleeding as those treated with warfarin, but lower healthcare resource utilization and costs.
Source: American Heart Journal - February 21, 2019 Category: Cardiology Source Type: research

Evaluation of the Influence of Etiological Factors on the Economic Burden of Ischemic Stroke in Younger Patients in China Using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Classification.
CONCLUSIONS In the younger patient population in China, etiological factors influenced the economic burden of ischemic stroke. PMID: 30666992 [PubMed - in process]
Source: Medical Science Monitor - January 24, 2019 Category: Research Tags: Med Sci Monit Source Type: research

Screening for undiagnosed atrial fibrillation.
Authors: Sandhu RK, Healey JS Abstract INTRODUCTION: Atrial fibrillation (AF) is a condition of global importance and it is associated with significant morbidity, mortality and healthcare costs. A considerable proportion of patients with AF are asymptomatic and stroke may be the first clinical manifestation of their AF diagnosis. AF screening provides an opportunity to identify patients with undetected AF prior to suffering a devastating complication. Areas covered: This review will provide a rationale for AF screening; summarize AF screening methods, studies and economic analyses; evaluate AF as a condition meetin...
Source: Expert Review of Cardiovascular Therapy - July 4, 2018 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Abstract 175: Atrial Fibrillation in the USF Resident Clinics: Quality-Driven Medical Therapy Session Title: Poster Session AM
Patients with atrial fibrillation (afib) have a high rate of serious complications including stroke and decompensated heart failure. While patients with afib are five times more likely to suffer a stroke in their lifetime than the general population, this risk can be reduced by 64% with appropriate anticoagulation using warfarin or approved novel oral anticoagulants (NOACs). Reducing the morbidity and mortality from excess strokes is a common interest nationwide due to unsustainable healthcare costs, increasing human resource gaps in medicine, and payment reforms that hold physicians and healthcare organizations financiall...
Source: Circulation: Cardiovascular Quality and Outcomes - April 5, 2018 Category: Cardiology Authors: Sadic, E. Tags: Session Title: Poster Session AM Source Type: research

Implications of stroke and bleeding risk-scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.
CONCLUSION: NVAF patients accrue variable healthcare costs. Stroke and bleeding risk should be taken into account during the creation of NVAF payment bundles. PMID: 29164990 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - November 23, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin
ConclusionPatients receiving dabigatran had significantly lower total all-cause, inpatient, and outpatient costs but higher pharmacy costs than those receiving warfarin. In addition, stroke-specific total and outpatient costs and bleed-specific total and inpatient costs were significantly lower in dabigatran users compared with warfarin users.
Source: American Journal of Cardiovascular Drugs - August 9, 2017 Category: Cardiology Source Type: research

Atrial fibrillation management in older heart failure patients: a complex clinical problem.
CONCLUSIONS: Large multicenter longitudinal studies are needed to examine the effects of VKAs and NOACs on long-term cognitive function and frailty; future studies should include geriatric conditions. PMID: 27924216 [PubMed - in process]
Source: Heart International - December 9, 2016 Category: Cardiology Tags: Heart Int Source Type: research

Update on atrial fibrillation
Atrial fibrillation (AF) is the most common arrhythmia and accounts for one-third of hospitalizations for rhythm disorders in the United States [1]. Atrial fibrillation is of public health importance and profoundly increases morbidity, mortality, and health-related expenditures. Morbidities include outcomes such as heart failure, stroke and the deleterious effects on quality of life (QOL), functional status, and cognition. In the United States and Western Europe, the aging population and the accompanying rise in the prevalence of AF have magnified its toll on morbidity and healthcare costs.
Source: Trends in Cardiovascular Medicine - June 21, 2016 Category: Cardiology Authors: Amanulla Khaji, Peter R. Kowey Source Type: research

The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review
AbstractThe aim of this study was to summarize healthcare costs incurred by patients with atrial fibrillation (AF) who developed ischaemic stroke, explore factors associated with increased cost, and highlight the importance of anticoagulation therapy for stroke prophylaxis. A systematic literature search of PubMed, EMBASE, Web of Science, and the health economic evaluation database was conducted up to December 2015. Studies focused on the cost and/or resource utilization of ischaemic stroke in patients with AF were included. Reported costs were converted to international dollars (I$) and adjusted to 2015 values. Alongside ...
Source: Europace - May 21, 2016 Category: Cardiology Source Type: research

Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal
Conclusions Apixaban is a cost-effective alternative to warfarin and dabigatran and is dominant over rivaroxaban in AF patients from the perspective of the Portuguese national healthcare system. These conclusions are based on indirect comparisons, but despite this limitation, the information is useful for healthcare decision-makers.
Source: Revista Portuguesa de Cardiologia - January 12, 2016 Category: Cardiology Source Type: research

The Problem With Predicting Postoperative Atrial Fibrillation
ATRIAL FIBRILLATION (AF) is the most common cardiac arrhythmia, with significant effects on patient quality of life and healthcare costs. Currently, more than 400,000 hospitalizations and 80,000 deaths annually are attributed to AF, with a substantial associated healthcare cost of $26 billion.1,2 Postoperative atrial fibrillation (POAF) is a unique entity seen in 16% to 30% of patients undergoing cardiac surgery and is associated with increased stroke, mortality, and hospital length of stay.3–5 The exact mechanism of POAF remains unknown, although it likely is multifactorial, caused by a combination of surgical stress an...
Source: Journal of Cardiothoracic and Vascular Anesthesia - September 16, 2015 Category: Anesthesiology Authors: Emily Methangkool, Kimberly Howard-Quijano, Aman Mahajan Tags: Editorial Source Type: research

Pages: 1  2  3